Background {#Sec1}
==========

The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization (WHO) workshop in 1999 (published in 2001) \[[@CR1]\]. The goals were (1) to propose a new allergic rhinitis (AR) classification using persistence and severity of symptoms in order to more closely reflect patients' needs, (2) to promote the concept of multi-morbidity in asthma and rhinitis as a key factor for patient management, (3) to develop guidelines with all stakeholders, (4) to include experts from developed and developing countries and (5) to initiate global implementation among health care professionals (HCPs) and patients.

Patients, clinicians and other HCPs are confronted with various treatment choices for the management of AR. This contributes to considerable variation in clinical practice. Worldwide, patients, clinicians and other HCPs are faced with uncertainty about the relative merits and downsides of the many AR treatment options available. The first ARIA workshop report used the Shekelle evidence-based methodology \[[@CR1], [@CR2]\]. It was the first guideline in chronic disease to assess multi-morbid conditions (i.e. asthma and rhinitis in the same patient). In 2008, ARIA was updated using the same evidence-based system \[[@CR3]\]. More transparent reporting of guidelines to facilitate understanding and acceptance was needed. In its 2010 Revision, ARIA was the first chronic respiratory disease guideline to adopt the GRADE (Grading of Recommendation, Assessment, Development and Evaluation) approach, an advanced evidence evaluation methodology \[[@CR4]--[@CR7]\]. A new revision is pending.

ARIA has been disseminated and is implemented in over 70 countries around the world \[[@CR8]\]. It is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK \[MACVIA (*Contre les Maladies Chroniques pour un Vieillissement Actif*)-ARIA Sentinel NetworK\] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves \[[@CR9]\].

The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status in order to reduce health and social inequalities incurred by the disease.

AIRWAYS ICPs: the ARIA 2016 political agenda {#Sec2}
============================================

In 2012, the European Commission launched the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA; DG Santé and DG CONNECT) to enhance EU competitiveness and tackle societal challenges through research and innovation \[[@CR10]\]. The B3 Action Plan is devoted to the scaling up and replication of successful innovative integrated care models for chronic diseases amongst older patients.

Chronic respiratory diseases were selected to be the pilot for chronic diseases of the EIP on AHA Action Plan B3 (Integrated care pathways for airway diseases, AIRWAYS ICPs) \[[@CR11], [@CR12]\] with a life cycle approach \[[@CR13]\]. Several effective plans exist in Europe for chronic respiratory diseases, but they are rarely deployed to other regions or countries.

AIRWAYS ICPs aims to launch a collaboration to develop practical multi-sectoral care pathways (i.e. ICPs) in European countries and regions to reduce chronic respiratory disease burden, mortality and multi-morbidity, while maintaining patients' quality-of-life (QOL) \[[@CR11], [@CR14]\]. AIRWAYS-ICPs proposes a feasible, achievable and manageable project (from science to guidelines and policies) using existing networks. It brings together key stakeholders including end users, public authorities, industry partners, involved in the innovation cycle, from research to adoption, as well as those engaged in standardisation and regulation. The Action Plan of AIRWAYS ICPs has been devised \[[@CR11]\], implemented \[[@CR14]\] and scaled up \[[@CR15]\].

AIRWAYS ICPs is a GARD (WHO Global Alliance against Chronic Respiratory Diseases) \[[@CR16]\] research demonstration project. Its deployment beyond Europe is carried out via GARD.

One AIRWAYS-ICPs activity is the development of multi-sectoral care pathways for rhinitis and asthma and their multi-morbidities, implementing emerging technologies for predictive medicine across the patient life cycle \[[@CR13]\].

From guidelines to integrated care pathways: MACVIA-ARIA Sentinel NetworK (MASK) {#Sec3}
================================================================================

Best practice, guideline and care pathways {#Sec4}
------------------------------------------

A *good* or *best practice* is a technique, method, process, activity, incentive, or reward believed to be more effective than any other technique, method, process, etc. when applied to a particular condition or circumstance. A best practice can be adopted as a standard process or be used as a guideline (U.S. Dept. of Veterans Affairs \[[@CR17]\]).

A *guideline* is a statement to determine a course of action. It aims to streamline particular processes according to a set routine or sound practice. By definition, following a guideline is never mandatory. Guidelines are not binding and are not enforced (U.S. Dept. of Veterans Affairs \[[@CR17]\]).

"*Clinical practice guidelines* are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances" (Institute of Medicine, 1990). These clinical practice guidelines define the role of specific diagnostic and treatment modalities. The statements include recommendations based on evidence intended to help HCPs and providers in their practice \[[@CR18]\].

*The Integrated Care Pathway* (ICP) concept was initiated in 1985 by Zander and Bower \[[@CR19]\]. ICPs are structured multi-disciplinary care plans detailing key steps of patient care for a given clinical problem \[[@CR20]\]. They promote the translation of guidelines into local protocols and their subsequent application to clinical practice. An ICP forms all or part of the clinical record, documents the care given, and facilitates the evaluation of outcomes for continuous quality improvement \[[@CR21]\]. They can help empower patients and their carers (health and social). ICPs differ from clinical practice guidelines as they are utilized by a multi-disciplinary team, and focus on the quality and co-ordination of care. ICPs need to have a mechanism for recording variations/deviations from planned care. Like guidelines, an ICP is a guide to treatment, and clinicians are free to exercise their own professional judgment as appropriate. However, any alteration to the practice identified within this ICP must be noted as a variance \[[@CR22]\]. Variance analysis is a critical part of developing and using ICPs \[[@CR23]\]. The resulting analysis can be used to amend the ICP itself if, for the majority of patients, the practice is different to the pathway (Table [1](#Tab1){ref-type="table"}).Table 1Definition of guidelines, practice protocols and ICPs.Adapted from <http://www.implementationcentral.com/guidelines_8.html>GuidelineClinical practice guidelinesCare pathwayFocusSpecific clinical circumstancesTreatment and/or preventionThe quality and co-ordination of careDefinitionSystematically developed statements to help practitioners and patients make decisions about appropriate health careA suggested course of treatment and/or treatment service for a specific diagnosis, functional deficit or problem areaStructured, multi-disciplinary plans of careGoalsMakes specific recommendations on health care and links these to research evidenceHighlights major therapeutic or preventive interventions\
Identifies choices of different courses or paths of treatmentSupports the implementation of clinical guidelines and protocolsOutputsProvides a summary and appraisal of the best available research evidence or expert consensus\
Highlights the strength of the evidence underlying each recommendation\
Describes barriers and facilitators for each recommendationProvides a logical flow of interventions. Provides detailed recommendations that build on those made in SPCs guidelinesProvides detailed guidance for each stage in the management of a patient and key performance indicatorsUsersClinicians, patients and third parties (all stakeholders involved)Specific to cliniciansA multidisciplinary clinical teamComponents(1) Appraisal of literature (research evidence or expert consensus)\
(2) Summary of recommendations\
(3) An outline of how guidelines should be implemented and how adherence monitoredList of major therapeutic or preventive interventions\
Goals: When interventions should be achieved\
Options for different choices of treatment and/or prevention(1) Timeline\
(2) Categories of care/intervention\
(3) Intermediate and long term outcome criteria\
(4) A variance record

Multisectoral care pathways for rhinitis and asthma using ICT {#Sec5}
-------------------------------------------------------------

A large number of AR patients do not consult physicians because they think their AR symptoms are 'normal' and/or trivial. However, AR negatively impacts social life, school and work productivity \[[@CR3]\]. Many AR patients use over the counter (OTC) drugs \[[@CR24]\] and only a fraction have had a medical consultation. The vast majority of patients who visit GPs or specialists have moderate/severe rhinitis \[[@CR25]--[@CR29]\]. Thus, ICPs should consider a multi-disciplinary approach as proposed by AIRWAYS ICPs (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Multi-sectoral care pathway for allergic rhinitis (from Bousquet et al. \[[@CR9]\])

The variations/deviations of the ARIA recommendations from planned care have been assessed and several unmet needs identified. Disease severity is associated with several health outcomes, including quality of life \[[@CR25]--[@CR29]\], and should be considered in ICPs. The duration of rhinitis (intermittent/severe-persistent) is an important indicator of asthma multi-morbidity (in some but not all studies) \[[@CR30]\], duration of AR treatment and efficacy of treatment in AR \[[@CR27]\]. Most patients receive combinations of oral antihistamines and intra-nasal corticosteroids (INS) \[[@CR31]--[@CR33]\] which are not evaluated in guidelines using an appropriate methodology.

Simple approach to assess control in allergic rhinitis {#Sec6}
------------------------------------------------------

In asthma, the management strategy is based on disease control, current treatment and future risk (exacerbations, lung function decline) \[[@CR34]--[@CR36]\]. In AR, the switch from symptom severity to disease control to guide treatment decisions has been led by ARIA and is now expanding to include MACVIA (a reference site of the EIP on AHA, EU \[[@CR37]\]) to form an Action Plan (MACVIA-ARIA). New developments which have facilitated this process include (1) the introduction of the visual analogue scale (VAS) as the common validated language of AR control, (2) categorization of AR control using VAS score cut-offs, (3) incorporation of this VAS into simple interactive apps for both patients (*ARIA Allergy Diary*) and HCPs (*ARIA Allergy Diary Companion*) \[[@CR9], [@CR38]\] and (4) the integration of all this knowledge into ICPs deployed by the EIP on AHA \[[@CR9]\].

The VAS represents a simple way of measuring control. It has been used in many diseases, including AR. VAS scores appear to be similar in different countries, for patients with moderate--severe intermittent or persistent rhinitis \[[@CR39], [@CR40]\]. An advantage of the VAS is that it can be used in all age groups, including preschool children (guardian evaluation) \[[@CR41]\] and the elderly \[[@CR42], [@CR43]\]. Furthermore, it can be used in a wide variety of languages \[[@CR39], [@CR40], [@CR42], [@CR44]--[@CR48]\]. VAS scores vary with ARIA AR classification in many languages \[[@CR28], [@CR44], [@CR49], [@CR50]\]. A VAS score of 50/100 mm suggests moderate--severe AR \[[@CR32], [@CR51], [@CR52]\], although in some studies this cut-off was \>60 mm \[[@CR45]\]. The VAS has been used to define severe chronic upper airway disease (SCUAD \[[@CR53]\]). The minimal clinically important difference (MCID) during treatment was found to be 2.3/10 cm in the French population \[[@CR54]\] and may be generalized to other countries, but future studies may refine this cut-off score. VAS score changes appear to encompass both symptoms and disease-specific QOL \[[@CR54], [@CR55]\].

As is the case for asthma, the best control of AR should be achieved as early as possible in order to (1) improve patient satisfaction and concordance with treatment and (2) reduce the AR burden including symptoms, reduced QoL, and school and work presenteeism/absenteeism. Untreated AR can impair driving ability and put patients at risk \[[@CR56]\]. The ultimate goal of AR control is to reduce the direct and indirect costs incurred by AR \[[@CR57]--[@CR60]\].

The variability in approaches to achieve disease control is challenging, and necessitates careful monitoring as well as the step up/step down of individualized therapeutic regimens over time. However, the challenges of managing AR are increased by the fact that patients do not often recognise their AR symptoms or confuse them with those of asthma or other multimorbidities such as rhinosinusitis \[[@CR61]\]. Therefore, it is important for patients, caregivers or HCPs to be able to use an AR symptom scoring system that is simple to use and rapidly responsive to change.

The aim is to encourage effective cross communication and achieve rapid and sustained disease control. MACVIA-ARIA has produced a simple VAS-based algorithm called the *ARIA Clinical Decision Support System* (CDSS) using a VAS score to guide treatment decisions in a step-up/step-down approach. This CDSS provides an individualized approach to AR pharmacotherapy (depending on medication availability and resources) \[[@CR62]\]. This approach holds the potential for optimal AR control while minimizing side effects and costs.

MASK (MACVIA-ARIA Sentinel NetworK): rhinitis and asthma {#Sec7}
--------------------------------------------------------

MASK-rhinitis and asthma is a simple ICT tool used to implement ICPs for AR and asthma by means of a common language (for patients and HCPs) and a CDSS. Disease control is assessed by VAS, incorporated into apps for patients (*ARIA Allergy Diary*) and HCPs (*ARIA Allergy Diary Companion*), with the utility to assess patient QoL (weekly EQ-5D) \[[@CR63], [@CR64]\] and school/work productivity (weekly WPAI-AS and daily VAS) \[[@CR25], [@CR65], [@CR66]\].

MASK-rhinitis and asthma will (1) allow patients and caregivers to screen for AR and asthma, and track their AR control (2) guide pharmacists in the prescription of OTC medications and referral of patients to physicians when appropriate, (3) allow primary care physicians to prescribe appropriate AR treatment, assess patients' AR control and direct follow-ups in accordance with the CDSS and (4) encourage referral to specialists and outpatient clinics, if there is failure to gain AR control at the primary care level.

MASK-rhinitis and asthma will be important for establishing care pathways across the life cycle. It will stratify patients with severe uncontrolled disease and achieve better results in prevention and intervention trials guided by the use of an individualised and predictive medicine approach.

The MASK tools: the *ARIA Allergy Diary* and *ARIA Allergy Diary Companion* apps {#Sec8}
--------------------------------------------------------------------------------

*The ARIA Allergy Diary* is freely available in 15 EU countries, Australia, Mexico and Switzerland and in 15 languages (translated and back-translated, culturally adapted and legally compliant). It will also be deployed in Brazil, Canada and the USA. The companion app will be available in Autumn 2016.

A pilot study was completed in AR during the pollen season to assess the relevance of the *ARIA Allergy Diary* app. It showed the importance of the tool to stratify patients, assess their work productivity and improve quality of life (EQ-5D) (Bousquet et al., submitted). Studies in asthma are planned for the autumn and winter.

### Questionnaires {#Sec9}

*ARIA Allergy Diary* users fill in simple questionnaires on asthma, rhinitis and the impact of the disease (globally, on work and school, on daily activities and on sleep) upon registration (Table [2](#Tab2){ref-type="table"}). The pilot study in around 5000 users (9% over 60 years of age) indicates that these questions are easily answered and can help to stratify patients with rhinitis.Table 2Baseline questionnaireQ1: I have rhinitis: yes/noQ2: I have asthma: yes/noQ3: My symptoms (tick) Runny nose Itchy nose Sneezing Congestion (blocked nose) Red eyes Itchy eyes Watery eyesQ4: How they affect me: my symptoms (tick) Affect my sleep Restrict my daily activities Restrict my participation in school or work Are troublesomeQ5: MedicationsQ6: Are you currently receiving immunotherapy (a small dose of the thing you are allergic to, usually taken as an injection or placed under your tongue)? yes/no If YES to Q6 (Q7 and Q8)Q7: What allergy is this? Grass pollen Parietaria pollen Birch pollen Other pollen Dust mite Animal Cypress tree pollen Don't know Add allergyQ8: How do you receive your treatment? Injection Tablet under the tongue Drops under the tongue Spray under the tongue Other

Moreover, two specific questionnaires are applied every week to assess disease impact on patients' QoL (EQ-5D) \[[@CR63], [@CR64]\] and productivity at work (WPAI-AS) \[[@CR25], [@CR65], [@CR66]\].

### Treatments received {#Sec10}

A list of all treatments available for asthma, conjunctivitis and rhinitis is included in the *ARIA Allergy Diary*, and users select the treatment(s) they are taking. Multiple treatments may be selected, and users can update the information when (or if) their treatment changes (Fig. [2](#Fig2){ref-type="fig"}). The list has been customized for all 20 countries in which the *ARIA Allergy Diary* is available, using data from IMS Health. Information on allergen specific immunotherapy is also requested on the day of first use. A questionnaire on biologics for asthma is under development.Fig. 2Screens on medications

### Daily visual analogue scales {#Sec11}

Geolocalized users assess their daily symptom control using the touchscreen functionality on their smart phone to click on 5 consecutive VASs (global symptoms due to allergic diseases, rhinitis, conjunctivitis, asthma and work productivity) (Fig. [3](#Fig3){ref-type="fig"}). These scales have been validated for AR and asthma criteria \[[@CR67]--[@CR71]\] and for work productivity (Bousquet et al., in preparation).Fig. 3Screens on daily visual analogue scales

### MASK-asthma {#Sec12}

Besides the asthma VAS, a test to measure pulmonary function is being developed. It is expected to be added to the *ARIA Allergy Diary* by the end of 2016.

### Clinical decision support system {#Sec13}

The MASK CDSS is incorporated into an app for HCPs (i.e. *ARIA Allergy Diary Companion*). This is essentially an algorithm to aid clinicians to select pharmacotherapy for patients with AR and to stratify their disease severity \[[@CR62]\]. It uses a simple step-up/step-down individualized approach to AR pharmacotherapy and may hold the potential for optimal control of symptoms, while minimizing side effects and costs. However, its use varies depending on the availability of medications in the different countries and on resources. A CDSS for asthma is also being developed.

### Ethics {#Sec14}

The terms of use have been translated into all languages and customized according to the country's legislation. They allow the use of anonymous data for research and commercial purposes. The app has a CE registration as a medical device class 1.

### Patient empowerment {#Sec15}

The validation of the *ARIA Allergy Diary* has already been accomplished (manuscript in preparation). With the help of patient organisations (EFA: European Federation of Allergy and Airways Diseases Patients' Associations), it will be evaluated and improved by the patients themselves.

New concepts in allergic multimorbidity embedded in ARIA {#Sec16}
========================================================

The term allergic multimorbidity is more appropriate than comorbidity since the primary allergic disease is poorly known \[[@CR72]\].

Stratification of severe allergic and/or asthma patients {#Sec17}
--------------------------------------------------------

Despite the major advances in understanding allergic diseases or asthma, treatments are not effective in all patients. From a clinical perspective, implementing knowledge-based decisions on what therapeutics to use for which patients and, if relevant, in which combinations, is extremely challenging. The aspiration to provide more effective therapeutic interventions tailored to the individual remains unfulfilled because of the variable response of individuals to such interventions. Patient stratification aims at grouping patients into disease sub-groups, where the specific pathological processes involved are better defined (clinical/molecular phenotypes).

Long-term birth cohort studies are essential for understanding the life course, early predictors, risk and protective factors of allergic diseases (including asthma and rhinitis) and the complex interplay between genes and environment (including life style and socio-economic determinants) \[[@CR73]\]. MeDALL (Mechanisms of the Development of ALLergy; EU FP7-CP-IP; Project No.: 261357; 2010--2015) attempted to better understand the complex links of allergic diseases at the clinical and mechanistic levels \[[@CR74]--[@CR76]\].

MeDALL identified a rare but severe allergy phenotype: polysensitized-multimorbid phenotype. Although multimorbidity is not always associated with allergy, studies in MeDALL \[[@CR77]\] on children, in the PARIS cohort at 2 years of age \[[@CR78]\], in EGEA on adults \[[@CR79], [@CR80]\] (Siroux, in preparation) and patient cohorts in subjects with peanut allergy \[[@CR81]\] all show that subjects who are polysensitized and multimorbid have a very high frequency of allergic symptoms, persistent symptoms over time, more severe asthma symptoms than other phenotypes and higher total and specific IgE levels.

Taken altogether, these results indicate that asthmatic patients cannot be managed appropriately without assessing rhinitis multimorbidity and also reinforce the importance of nasal problems (rhinitis and/or rhinosinusitis) in many uncontrolled asthmatic patients \[[@CR82]--[@CR84]\].

Allergic multimorbidity in old age adults {#Sec18}
-----------------------------------------

Asthma and rhinitis often start in early age and persist in most, but not all, subjects. The expected epidemic wave of asthma and rhinitis in older adults is an insufficiently recognized problem. In Europe, over 20% of adults suffer from AR and over 5% from asthma. These patients are now reaching the age of 65 years and a new health problem in older adults will be to understand, detect and manage these patients. Asthma and rhinitis in older adults have specific symptoms and treatment needs, which are different from those in younger adults. These patients also suffer from multi-morbididy with high rates of poly-pharmacy reported. Integrated Care Pathways (ICPs) for rhinitis and asthma should cover the entire life cycle.

The scaling up strategy {#Sec19}
=======================

The EIP on AHA has proposed a 5-step framework for developing an individual scaling up strategy: (1) what to scale up: (1-a) databases of good practices, (1-b) assessment of viability of the scaling up of good practices, (1-c) classification of good practices for local replication and (2) how to scale up: (2-a) facilitating partnerships for scaling up, (2-b) implementation of key success factors and lessons learnt, including emerging technologies for individualised and predictive medicine. This strategy has already been applied to the chronic respiratory diseases action plan of the EIP on AHA \[[@CR15]\].

There is an urgent need for scaling up strategies in order to (1) avoid fragmentation, (2) improve health care delivery across Europe, (3) speed up the implementation of good practices using existing cost-effective success stories and (4) meet the EIP on AHA objectives \[[@CR10]\].

Reference Site Collaborate Network (RSCN) of the EIP on AHA {#Sec20}
-----------------------------------------------------------

The RSCN brings together all EIP on AHA Reference Sites, and Candidate Reference Sites, across Europe into a single forum. The aim is to promote cooperation and develop and promote areas of innovative good practice and solutions, which contribute to improved health and care outcomes for citizens across Europe. The hope is to develop sustainable economic growth and create jobs. Members of 13 EIP on AHA Reference Sites (2013) have agreed on the AIRWAYS ICPs concept and are co-authors of the paper published in Clinical Translational Allergy \[[@CR15]\]. A meeting of all EIP on AHA Reference Sites was co-organised by the Région LR, North England \[[@CR85]\] and the EIP on AHA Reference Site Collaborative Network to scale up AIRWAYS ICPs in all Reference Sites (October 21, 2014). 74 EIP on AHA Reference Sites have now been approved by the EU (2016). A Twinning project has also been approved by the EIP on AHA to deploy MASK in 13 Reference Sites in order to compare allergic rhinitis diagnoses by allergists in adults and older people to study phenotypes, treatments and care pathways of rhinitis.

Conclusion {#Sec21}
==========

ARIA has evolved from a rigorously developed guideline to a mobile technology-based implementation strategy in order to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status with the aim to reduce health and social inequalities incurred by this very common disease globally.
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